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Abstract
Background: Nuclear bodies, such as nucleoli, PML bodies, and SC35 speckles, are dynamic sub-nuclear structures
that regulate multiple genetic and epigenetic processes. Additional regulation is provided by RNA/DNA handling
proteins, notably TDP-43 and FUS, which have been linked to ALS pathology. Previous work showed that mouse
cell line myotubes have fewer but larger nucleoli than myoblasts, and we had found that nuclear aggregation of
TDP-43 in human myotubes was induced by expression of DUX4-FL, a transcription factor that is aberrantly
expressed and causes pathology in facioscapulohumeral dystrophy (FSHD). However, questions remained about
nuclear bodies in human myogenesis and in muscle disease.
Methods: We examined nucleoli, PML bodies, SC35 speckles, TDP-43, and FUS in myoblasts and myotubes derived
from healthy donors and from patients with FSHD, laminin-alpha-2-deficiency (MDC1A), and alpha-sarcoglycan-
deficiency (LGMD2D). We further examined how these nuclear bodies and proteins were affected by DUX4-FL
expression.
Results: We found that nucleoli, PML bodies, and SC35 speckles reorganized during differentiation in vitro, with all
three becoming less abundant in myotube vs. myoblast nuclei. In addition, though PML bodies did not change in
size, both nucleoli and SC35 speckles were larger in myotube than myoblast nuclei. Similar patterns of nuclear body
reorganization occurred in healthy control, MDC1A, and LGMD2D cultures, as well as in the large fraction of nuclei
that did not show DUX4-FL expression in FSHD cultures. In contrast, nuclei that expressed endogenous or
exogenous DUX4-FL, though retaining normal nucleoli, showed disrupted morphology of some PML bodies and
most SC35 speckles and also co-aggregation of FUS with TDP-43.
Conclusions: Nucleoli, PML bodies, and SC35 speckles reorganize during human myotube formation in vitro. These
nuclear body reorganizations are likely needed to carry out the distinct gene transcription and splicing patterns that
are induced upon myotube formation. DUX4-FL-induced disruption of some PML bodies and most SC35 speckles,
along with co-aggregation of TDP-43 and FUS, could contribute to pathogenesis in FSHD, perhaps by locally
interfering with genetic and epigenetic regulation of gene expression in the small subset of nuclei that express
high levels of DUX4-FL at any one time.
Keywords: DUX4, FUS, Facioscapulohumeral muscular dystrophy, Myotube, Nucleoli, PML bodies, SC35 speckles,
TDP-43
* Correspondence: millerjb@bu.edu
1Department of Neurology, Boston University School of Medicine, Boston,
MA 02118, USA
3Neuromuscular Biology & Disease Group, Department of Neurology, Boston
University School of Medicine, 700 Albany Street, Boston, MA 02118, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Homma et al. Skeletal Muscle  (2016) 6:42 
DOI 10.1186/s13395-016-0113-7
Background
During the formation of skeletal muscle, myoblasts stop
proliferating and fuse with each other to form multinucle-
ate myofibers. A large number of genes undergo changes
in expression upon the myoblast to myofiber transition,
and myofiber gene expression is often disrupted in muscle
diseases. Many of the molecular mechanisms that underlie
genetic and epigenetic regulation of skeletal muscle gene
expression in normal development and in muscle disease
are now understood in considerable detail [1–7], but ques-
tions still remain about gene regulation in both myogen-
esis and muscle diseases.
In this study, we show that multiple sub-nuclear struc-
tures (i.e., nuclear bodies) reorganize during myotube
formation in primary cultures of human myogenic cells.
In addition, we further examine how nuclear bodies and
additional nuclear proteins are affected by disease, using
cultures of myogenic cells obtained from patients with
muscle diseases. In particular, we examine myogenic
cells obtained from donors with (i) congenital muscular
dystrophy type 1A (MDC1A) due to laminin-alpha-2-de-
ficiency, (ii) limb-girdle muscular dystrophy type 2D
(LGMD2D) due to alpha-sarcoglycan-deficiency, and (iii)
facioscapulohumeral muscular dystrophy (FSHD) type 1.
FSHD type 1 is caused by genetic and epigenetic changes
that promote aberrant expression of a full-length isoform
of DUX4 (DUX4-FL), which is a highly cytotoxic transcrip-
tion factor with a double homeodomain region [4, 8, 9]. A
shorter isoform, DUX4-S, that lacks the C-terminal trans-
activation domain but retains the two homeodomains, is
much less cytotoxic [10–12].
Nuclear bodies, such as the nucleoli, PML bodies, and
SC35 speckles studied in this work, are dynamic sub-
nuclear organelles that carry out different genetic and
epigenetic processes of gene regulation [13, 14]. Nucleoli
are sites of rDNA gene transcription, pre-rRNA process-
ing, and initial pre-ribosome assembly; a previous study of
mouse C2C12 cells showed that nucleoli were fewer in
number but larger in size in myotube nuclei compared to
myoblast nuclei [15]. PML bodies function in DNA repair,
transcription, and protein stability, including in stress
responses [13, 14], but little was known of PML bodies in
myogenesis. Nuclear speckles that contain the SC35 pro-
tein include pre-mRNA splicing factors, and transcription
sites for specific genes localize near SC35 speckles in myo-
nuclei [16]. Additional gene regulation is provided by
RNA/DNA handling proteins, notably TDP-43 and FUS,
mutations of which have been linked to pathogenesis in
some cases of amyotrophic lateral sclerosis (ALS) [17].
In a previous study, we found that expression of
DUX4-FL, but not DUX4-S, induced nuclear, but not
cytoplasmic, aggregates of TDP-43 [18]. DUX4-FL itself
also forms aggregates in a subset of the nuclei in which
it is expressed [18, 19], though DUX4-FL and TDP-43
do not appear to form co-aggregates [18]. To determine
if DUX4-FL or TDP-43 co-aggregated with particular
nuclear bodies or proteins, we have now carried out fur-
ther studies on nucleoli, PML bodies, and SC35 speckles
plus FUS. During these studies, we found that each of
these three nuclear bodies reorganizes during myotube
formation and that DUX4-FL expression can differen-
tially disrupt nuclear body morphology and also lead to
co-aggregation of FUS with TDP-43.
Methods
Cells and culture
All human cells used in this were obtained either from the
Muscle Tissue Culture Collection (MTCC) at the Univer-
sity of Munich or from the Wellstone FSHD Cell Biobank
which was at the Boston Biomedical Research Institute
and is now located at the University of Massachusetts
School of Medicine. The cells were anonymized prior to
receipt with no personal identifying information available
to us. The cells had been produced prior to our study
from muscle biopsies collected under protocols approved
by the appropriate institution that included informed
donor consent and approval to publish results in accord-
ance with standards of the Helsinki Declaration. Because
our studies were of human cells that were obtained from a
cell bank and for which personal identification data were
not obtainable by us, the studies were classified as exempt
from Human Studies review by the Boston University
Institutional Review Board in accordance with the US
Department of Heath and Human Services policy.
The human primary myogenic cells were grown on
gelatin-coated dishes in high-serum medium for prolifer-
ation and were switched when near confluence to low-
serum medium for differentiation as described [20, 21].
Myogenic cells from healthy control donors (07Udel,
09Ubic, 15Vbic, and 17Ubic) and from donors with
FSHD type 1 (07Adel, 09Abic, 12Adel, 16Abic, 17Abic
and 17Adel, 22Abic) or MDC1A (38/03, 50/04, 96/04)
were as described previously [20–23]. Myogenic cells
from LGMD2D donors were designated by the MTCC as
161/06 (3-year-old male donor with C100T Arg34Cys +
C229T Arg77Cys mutations in SCGA encoding alpha-
sarcoglycan) and 465/03 (5-year-old male donor with
homozygous C229TArg77Cys mutations in SCGA). When
directly compared, we found no differences in the patterns
of nuclear body reorganizations or FUS properties between
cultures derived from different donors with the same dis-
ease or between cultures of healthy control cells that were
derived from different donors.
To confirm authenticity, the primary cells were assessed
for genetic mutation; SNP pattern [21]; expression of
endogenous DUX4-FL in FSHD myotubes [21]; lack of
laminin-a2 expression in MDC1A myotubes; and/or lack
of expression or aberrant localization of a-sarcoglycan in
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LGMD2D myotubes [22, 23]. Cultures were also regularly
assessed for myoblast proliferation rate, proportion of
desmin-positive cells, and extent of myotube formation.
All cultures were used at <45 total population doublings,
which was well prior to the slowing of proliferation rate
that occurred at ~55–60 population doublings under our
culture conditions.
Immunostaining
As in our previous studies [18], the cultures of differenti-
ated cells were washed twice with PBS and then fixed with
2% paraformaldehyde (PFA) or ice-cold 100% methanol
for 10 min as found to be appropriate for the primary
antibody in preliminary validation experiments. Fixed
cultures were washed three times with PBS. PFA-fixed
cultures were additionally permeabilized with 0.5% Triton
X-100 for 10 min at room temperature. All fixed cultures
were blocked for 60 min at room temperature in 4% horse
serum, 4% goat serum (Thermo Fisher), and 4% bovine
serum albumin (EMD Millipore, Billerica, MA) in PBS
plus 0.1% Triton X-100. Fixed and blocked cultures were
incubated overnight at 4 °C with primary antibody diluted
in blocking solution as noted below. The following day,
the cells were rinsed three times with PBS and incubated
for 1 h with the appropriate secondary antibody diluted
1:500 in blocking solution. For double immunostaining,
the cultures were subsequently incubated as above with
the second primary antibody, washed as above, and incu-
bated with the second secondary antibody.
Antibodies
DUX4-FL was detected with rabbit anti-DUX4-FL mAb
E55 [10] used at 1:200 dilution (cat. ab124699, Abcam,
Cambridge, MA). Myosin heavy chain (MyHC) isoforms
were detected with mouse mAbs F59 [24] or MF20 [25]
(Developmental Studies Hybridoma Bank, Iowa City, IA)
used at 1:10 dilution of hybridoma supernatant or with
rabbit anti-MYH3 pAb (cat. HPA021808, Lot A75757;
Sigma-Aldrich, St. Louis MO) used at 1:500. Nucleolin
was detected with a mouse mAb (cat. ab13541; lot
GR217162-5 Abcam) used at 1:400. PML was detected
with a mouse mAb (cat. sc-966, Santa Cruz Biotech,
Dallas TX) used at 1:200. SC35 was detected with a
mouse mAb (cat. ab11826, lot GR272322-1; Abcam)
used at 1:1000. FUS was detected with a rabbit pAb (cat.
11570-1-AP, lot 00024677; ProteinTech, Rosemont
Illinois) used at 1:200. TDP-43 was detected with either
rabbit anti-TARDBP pAb (cat. 10782-2-AP; Proteintech)
or mouse anti-TDP-43 mAb (cat. 60019-2; Proteintech)
used at 1:200 dilution. Rabbit anti-PITX1 (Dixit et al.)
was a gift of Dr. Yi-Wen Chen and was used at 1:500.
V5 epitope tag was detected using either mouse anti-V5
mAb (cat. R960-25, Thermo Fisher) used at 1:500 or a
rabbit pAb (cat. AB3792, EMD Millipore) used at 1:300.
Each of the primary antibodies we used was validated
based on one or more methods, including prior use in
multiple published studies with the same mAb or lot of
polyclonal antiserum, manufacturer’s validation assays
including knockouts, generation of expected immuno-
fluorescence staining patterns, detection of appropriate
band size on immunoblots without detection of non-
specific bands, and detection of recombinant protein
when expressed in cells that normally do not express the
protein. Primary antibody binding was visualized with ap-
propriate species-specific secondary antibodies (Thermo
Fisher) conjugated to either Alexa Fluor 488 or Alexa
Fluor 594 and used at 1:500. Nuclei were stained with
bisbenzimide.
Microscopy
Images of immunostained cultures were acquired using a
Nikon E800 microscope with a Spot camera and software
version 5.1 (Diagnostic Instruments Inc., Sterling Heights,
Michigan). Numbers of nuclear bodies were quantified
either manually or with the counting application of the
software. Cross-sectional areas of nuclear bodies were
determined using the area application of the software to
measure areas of manually delineated outlines of the
structures. For different measurements, we cross-validated
outcomes by showing that comparable results were ob-
tained from healthy and/or diseased cell cultures by two
or three independent observers. In addition, we verified
that sample sizes were sufficient by showing in healthy
and/or diseased cell cultures that similar results were
obtained from analyses of multiple, independently identi-
fied groups of specified sample sizes.
BacMam vectors
BacMam vectors were derived from pCMV-DUX4-fl-V5
and pCMV-DUX4-s-V5 [12, 18] by EcoRI/XbaI restric-
tion digest and cloning of the corresponding DUX4
inserts into pENTR1A (Life Technologies) which was
prepared by digestion with EcoRI and XbaI. The result-
ing entry clones were recombined into the BacMam
destination vector pJiF2 using LR ClonaseII (Life
Technologies) and recombinant baculovirus generated
using the Tn7 transposition system [26]. The PITX1
BacMam vector was prepared by Gateway recombinase
reaction of the PITX1 clone BC003685 (obtained from the
MGH Center for Computational and Integrative Biology)
with the BacMam vector pHTBV1.1. The resulting plas-
mid was inserted into the baculoviral genome also using
the Tn7 transposition system [26] and transfected onto
Sf9 cells to generate recombinant baculovirus. In the
BacMam vectors, expression was driven by a human
CMV-IE1 promoter. P2 or P3 viral supernatants were
used in all experiments without further purification and
expression was analyzed at 24–48 h after addition.
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Results
Nucleoli reorganize during myogenesis and are not
affected by DUX4-FL
In cultures of myogenic cells from human healthy con-
trols, we identified nucleoli by immunofluorescence stain-
ing for nucleolin and found that myoblast nuclei typically
contained about three to six small nucleoli, whereas myo-
tube nuclei typically contained one to three nucleoli
(Fig. 1a–c). For myoblasts, the mean ± s.e.m. number of
nucleoli was 4.7 ± 0.13, and for myotubes, the number was
2.0 ± 0.12, which was significantly fewer than that in
myoblasts (P < 0.01, t test, nucleoli were counted in n = 50
nuclei). This pattern is very similar to that found previ-
ously in cultures of the mouse C2C12 myogenic cell line
where myoblast nuclei had an average of 5.3 nucleoli and
myotube nuclei had an average of 1.7 [15]. In addition to
decreasing in number, the nucleoli in myotubes formed
from healthy control myoblasts were also larger on
average than the nucleoli in myoblasts (Fig. 1d).
To determine if nucleolar reorganization was affected
by disease, we examined nucleolar numbers and cross-
sectional areas in cultures of myogenic cells from
MDC1A, LGMD2D, and FSHD donors (Fig. 1c, d). In
cultures of cells obtained from donors with each of these
diseases, we found the same patterns of nucleolar
reorganization as in healthy controls. That is, nucleoli in
myotubes were fewer in number but larger in size than
those in myoblasts. Thus, disease status did not affect
nucleolar reorganization during myotube formation. We
chose to examine these three diseases due to their distinct
types of causative mutations and pathogenic mechanisms.
MDC1A is due to mutation of an extracellular protein
(laminin-a2), whereas LGMD2D is due to mutation of a
sarcolemmal protein (a-sarcoglycan) and FSHD is due to
genetic and epigenetic alterations that lead to aberrant
expression of a nuclear transcription factor (DUX4-FL).
To determine if nucleolar structure might be affected
in the small fraction (0.01–0.1%) of myotube nuclei that
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Fig. 1 Myotubes had fewer, but larger, nucleoli than myoblasts. Immunostaining for nucleolin (green) was used to identify nucleoli and staining for
myosin heavy chain (red) was used to distinguish nuclei in myotubes from those in myoblasts. a, a’ Myoblast nuclei, three of which are shown,
typically had four or five nucleoli. b, b’ Myotube nuclei, of which four are shown from a single myotube, usually had one to three nucleoli that were
typically larger than those in the myoblast nuclei. c Quantitation of nucleoli in myoblasts (light gray bars) and myotubes (dark gray bars) in cultures of
healthy control, MDC1A, DUX4-negative FSHD, and LGMD2D myogenic cells. All cultures showed similar decreases in nucleolar number in myotube vs.
myoblast nuclei. Error bars = s.e.m. **P < 0.01 by t test. Nucleoli were counted in n = 50 nuclei. d Quantitation of the cross-sectional areas of nucleoli in
myoblasts (light gray bars) and myotubes (dark gray bars) in cultures of healthy control, MDC1A, DUX4-negative FSHD, and LGMD2D myogenic cells.
All cultures showed similar increases in nucleolar size in myotube vs. myoblast nuclei. Scale bar in A = 20 μm. Error bars= s.e.m. **P < 0.01 by t test.
Number of nucleoli measured as indicated on each data bar
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express DUX4-FL in FSHD cultures, we examined the
effect of exogenous and endogenous DUX4-FL expres-
sion on nucleoli. To identify endogenous DUX4-FL
expression, we examined differentiated cultures of myo-
genic cells obtained from FSHD patients with mAb E55
that is specific for the unique C-terminal region of
DUX4-FL [10]. Consistent with previous studies [10, 21],
DUX4-FL was expressed in only a small fraction of myo-
tube nuclei and, within myotubes, there was typically a
gradient of staining intensity among nuclei (Fig. 2a, b;
but see Fig. 7a for a myotube with uniform intensity of
DUX4-FL staining). As we noted in our previous study
[18], endogenous DUX4-FL staining is often found in a
punctate pattern in some nuclei (e.g., as in Fig. 2a, b)
indicating aggregation but is more uniformly distributed
in other nuclei. In different experiments, the percentage
of nuclei with punctate DUX4-FL staining varied consid-
erably for unknown reasons. In a typical study, however,
about a quarter of the DUX4-FL-positive nuclei showed
an obviously punctate DUX4-FL staining pattern.
For exogenous expression, we used a BacMam vector to
express DUX4-FL in myoblasts and myotubes in cultures
of healthy control myogenic cells as in our previous work
[18]. Expression of exogenous DUX4-FL was identified
with either the E55 mAb or with an anti-V5 mAb that
recognizes a C-terminus epitope tag on the expressed pro-
tein. Consistent with our previous work, we found that a
large fraction of nuclei showed staining for exogenous
DUX4-FL at both 24 and 48 h after BacMam addition.
Also, as for the endogenously expressed DUX4-FL, we
found both punctate (Fig. 2c) and more uniform (Fig. 2d)
staining patterns for exogenous DUX4-FL.
By double immunofluorescence, we did not find any
obvious differences in nucleolar number or morphology
in DUX4-positive vs. DUX4-negative nuclei (Fig. 2a–d),
and this finding was the same for both endogenous and
exogenous DUX4-FL and also for nuclei with punctate
and uniform DUX4-FL staining patterns. Furthermore,
in those nuclei with punctate DUX4-FL staining, the
nucleolin and DUX4-FL stains did not overlap, indicat-
ing that DUX4-FL did not co-aggregate with nucleoli
(Fig. 2a–c). BacMam-mediated expression of DUX4-S
also did not alter nucleoli (Fig. 2e).
PML bodies reorganize during myogenesis and a small
fraction of PML bodies are disrupted by DUX4-FL
We quantified nuclear PML bodies that were identified
by immunofluorescence staining for the PML protein
and found that myoblast nuclei typically contained about
15–20 small round PML bodies (Fig. 3a). Myotube
nuclei, in contrast, usually had only four to eight PML
bodies (Fig. 3b). Quantitation showed that cultures of
myogenic cells from healthy controls, as well as from
MDC1A, LGMD2D, and FSHD donors, all showed similar
decreases in the number of PML bodies in myotube nuclei
compared to myoblast nuclei (Fig. 3c). Unlike nucleoli, we
did not find a difference in the average size of PML bodies
between myoblasts and myotubes in healthy control,
MDC1A, LGMD2D, or FSHD cultures (Fig. 3d). As an
example, in a healthy control culture, PML bodies had an
Endogenous 
   DUX4-FL               Nucleolin                  Merge 
 Exogenous 
   DUX4-FL               Nucleolin                  Merge 
 Exogenous 
   DUX4-S                 Nucleolin                   Merge 
Fig. 2 Nucleoli appeared to be unaffected by expression of DUX4-FL.
a–b” Staining for endogenously expressed DUX4-FL (red) and nucleolin
(green) in three nuclei within a single myotube. In these nuclei, DUX4-FL
expression did not appear to affect nucleolar structure, and there was
little or no overlap of punctate staining for DUX4-FL with nucleolin. In
all panels, dotted lines indicate approximate borders of individual nuclei.
c–d” Staining for endogenously expressed DUX4-FL (red) and nucleolin
(green) in several nuclei within a single myotube. Exogenous DUX4-FL
expression, whether predominantly punctate (c) or predominantly
uniform (d) also did not appear to affect nucleolar structure, and there
was also little or no overlap of exogenous DUX4-FL and nucleolin
staining. e–e” When expressed in myotubes, the non-cytotoxic, short
DUX-S isoform was uniformly distributed in nuclei and did not appear
to affect nucleolar structure. Bar in A = 20 μm for rows a–d and 15 μm
for row e
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average cross-sectional area of 0.34 ± 0.16 μm2 in myo-
blasts (ave ± SD, n = 196) and 0.35 ± 0.19 μm2 in myotubes
(ave ± SD, n = 81) (P = 0.47 by unpaired t test).
Though disease status did not affect the overall pattern
of PML body reorganization during myotube formation,
DUX4-FL expression did appear to lead to disrupted
organization of a small subset of PML bodies. In most
nuclei that expressed endogenous or exogenous DUX4-
FL, with either uniform and punctate staining, the PML
bodies appeared to have normal morphology and there
was little evidence of interaction between DUX4-FL and
PML bodies (Fig. 3e) or between DUX4-S and PML
bodies (Fig. 3f ). However, in DUX4-FL-positive nuclei,
there was a small fraction (~5–15% in different experi-
ments) of nuclei that showed one or more PML bodies
with disrupted organization, sometimes with close ap-
position to or intermingling with DUX4-FL aggregates
(Fig. 4). For example, in some of these nuclei, PML
PML
A. Myoblasts   B.Myotube        C. 
D. 
* * * 
Fig. 3 Myotubes had fewer PML bodies than myoblasts and the structure of most PML bodies was not affected by DUX4-FL expression. a Human
myoblasts from a healthy donor typically had 10 to 20 or sometimes more PML-positive structures (green). b Nuclei in myotubes typically had four
to eight PML bodies. c Quantitation of PML bodies in myoblasts (light gray bars) and myotubes (dark gray bars) in healthy control, MDC1A, DUX4-
FL-negative, and LGMD2D myogenic cells. All cultures showed similar decreases in PML body number in myotube vs. myoblast nuclei. Error bars
= s.e.m. **P < 0.01 by t test, with all PML bodies counted in n = 50 nuclei. d Quantitation of the cross-sectional areas of PML bodies in myoblasts
(light gray bars) and myotubes (dark gray bars) in healthy control, MDC1A, DUX4-FL-negative FSHD, and LGMD2D myogenic cells. All cultures
showed no significant changes in PML body size in myotube vs. myoblast nuclei. Error bars = s.e.m. n.s. not significant (P > 0.05) by t test. Number
of PML bodies measured as indicated on each bar. e–e” In most, but not all (see Fig. 4), nuclei with punctate DUX4-FL fluorescence, PML bodies
showed minor or no disruption, and there was little overlap between DUX4-FL and PML fluorescence. Nuclei in myotubes are shown. Arrow =
DUX4-FL-positive nucleus, asterisk = DUX4-FL-negative nucleus. f–f” DUX4-S was typically uniformly distributed within the nuclei, and expression
of DUX4-S did not affect PML body morphology. Nuclei in myotubes are shown. Bar in a = 20 μm for a, b, f, and 15 μm for e
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staining appeared to be wrapped around DUX4-FL
aggregates (Fig. 4a, b), and in others, PML appeared to
be integrated within or wrapped around a group of
small, closely spaced DUX4-FL aggregates (Fig. 4c, d).
SC35 speckles reorganize during myogenesis and speckle
patterns in most nuclei are disrupted by DUX4-FL
We quantified SC35-containing speckles by immuno-
fluorescence staining for SC35 and found that myoblast
nuclei typically contained about 25–30 small speckles.
Myotube nuclei, in contrast, usually had about 20
speckles, which was significantly less than the number in
myoblasts (Fig. 5a–c). Myotube nuclei from MDC1A,
LGMD2D, and FSHD patients all had significantly fewer
SC35 speckles than myoblast nuclei and the decreases
were of similar magnitudes (Fig. 5c). In addition, SC35
speckles in myotube nuclei had, on average, significantly
larger cross-sectional areas than speckles in myoblast
nuclei (Fig. 5d). Healthy control cultures, as well as
MDC1A, LGMD2D, and FSHD cultures, all showed an
increased speckle size in myotube vs. myoblast nuclei.
The morphology of SC35 speckles was altered in a ma-
jority of nuclei upon exogenous (Fig. 6a–c) or endogen-
ous (Fig. 7a–d) expression of DUX4-FL. The pattern of
SC35 speckles in DUX4-FL-negative nuclei showed little
variation, with most nuclei containing 20–30 speckles of
similar sizes and somewhat fuzzy outlines distributed
throughout the nucleus (Fig. 5 and nuclei marked by
asterisks in Figs. 6a–c and 7a–d). In contrast, SC35
speckles in exogenous or endogenous DUX4-FL-positive
nuclei showed an altered range of morphologies and
numbers. In particular, the most frequent change in
DUX4-FL-positive nuclei was the appearance of one or
more very large, irregularly shaped regions of intense
SC35 staining (Figs. 6b, 7a middle nucleus, d), and the
second most common change was the appearance of a
reduced number of larger than usual, round speckles
(Figs. 6a, c and 7c). Other abnormal patterns that were
uncommon included a relatively uniform, low-intensity
staining (Fig. 7a, rightmost nucleus) and an open, disor-
ganized staining (Fig. 7b). In addition, as noted in the
blind test, SC35 speckle staining did not appear to be
significantly affected in some DUX4-FL-positive nuclei
(Fig. 7a, leftmost nucleus)
To further assess this result, we carried out a blind test
to confirm that the SC35 staining patterns in DUX4-FL-
positive and DUX4-FL-negative nuclei were distinctive.
For this test, observers were provided with unlabeled
DUX4-FL                  PML                    Merge 
A                               
B                              
C                              
D                              
Fig. 4 The structures of PML bodies in a small fraction of nuclei were disrupted by DUX4-FL expression. Each row shows one myotube nucleus
immunostained as indicated for DUX4-FL or PML along with a merged image. Dotted lines show the approximate outlines of each nucleus. In
rows a–a” and b–b”, the arrows point to regions where PML staining appears to envelop DUX4-FL aggregates; and in rows c–c” and d–d”, the
arrows point to PML staining that appears to be intertwined with small DUX4-FL aggregates. Bar in a = 10 μm
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images of SC35 immunofluorescence and were asked to
classify the SC35 staining pattern in each nucleus as
“obviously different,” “maybe different,” or “the same as”
the pattern seen in the healthy control cells. Each image
contained many nuclei (range 12–1, ave = 19.8, total =
1109). After the observers had classified all nuclei, the
SC35 images were compared to companion images of
the same fields that had been immunostained for
DUX4-FL, expressed either from the BacMam vector or
from its endogenous promoter. The study was designed
so that about half of the images had no DUX4-FL-
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Fig. 5 SC35-containing speckles in myotube nuclei were fewer in
number but larger in size than those in myoblast nuclei. a, b
Immunostaining for SC35 (red) was used to identify SC35 speckles
and staining for myosin heavy chain (green) was used to identify
myotubes and thus distinguish nuclei in myotubes from those in
myoblasts. SC35 speckles in myotube nuclei typically appeared to be
fewer in number and sometimes larger than those in myoblasts. c
Quantitation of the number of SC35 speckles in myoblast nuclei
(mb, light gray bars) and in myotube nuclei (mt, dark gray bars). As
indicated, speckles were counted in healthy control, MDC1A, and
LGMD2D myogenic cells, as well as in the DUX4-FL-negative nuclei
of FSHD myogenic cells. In each type of cells, the average number
of SC35 speckles was lower in myotube nuclei than in myoblast
nuclei. Error bars = s.e.m. **P < 0.01 by t test. Speckles were counted
in n = 50 nuclei. d Quantitation of the cross-sectional areas (μm2) of
SC35 speckles in myoblasts (mb, light gray bars) and myotubes (mt,
dark gray bars). As indicated, speckles were measured in healthy
control, MDC1A, and LGMD2D myogenic cells, as well as in the
DUX4-FL-negative nuclei of FSHD myogenic cells. In each type of
cell, the average size of SC35 speckles was higher in myotube nuclei
than in myoblast nuclei. Error bars = s.e.m. **P < 0.01 by t test. The
number of speckles measured is indicated on each bar. Bar
in a = 20 μm
Exogenous 
  DUX4-FL        SC35           Merge           Nuclei 
*       * *       * *       * *       * 
    PITX1           SC35           Merge           Nuclei 
* * * * 
   DUX4-S         SC35           Merge           Nuclei 






Fig. 6 SC35 speckles in most nuclei were disrupted by exogenous
DUX4-FL expression. a–c BacMam-mediated expression of DUX4-FL
(green) in healthy control myotubes caused SC35 speckles (red) to
show an altered morphology. Arrows indicate nuclei that expressed
DUX4-FL, and asterisks indicate nearby nuclei that were DUX4-FL-
negative. SC35 speckles in the DUX4-FL-positive nuclei typically
showed larger aggregates and/or more intense staining. SC35
speckles were disrupted in both nuclei with punctate DUX4-FL
staining (rows a, c) and in nuclei with uniform DUX4-FL staining
(row b). In nuclei with punctate DUX4-FL (rows a, c), there was little
or no overlap between DUX4-FL and SC35 staining. d, e In contrast
to expression of DUX4-FL, exogenous, BacMam-mediated expression
of DUX4-S (row d) or PITX1 (row e) did not markedly affect SC35
speckles in most nuclei. See Fig. 7e for quantitation of the extent to
which exogenous DUX4-FL, DUX4-S, and PITX1 affects SC35 speckles
using blind assays. Bar in b = 20 μm for a, b, d, and e and 12 μm for c
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or more. (For this study, we used an amount of BacMam
that generated expression in about 5% of the nuclei in
these cultures of healthy control cells.) For BacMam-
mediated expression of DUX4-FL, the observers classi-
fied 28 of the 33 (85%) DUX4-FL-positive nuclei in the
blind image set as obviously different, and the remaining
five DUX4-FL-positive nuclei were classified as maybe
different, whereas only one or two nuclei would have
been expected to be correctly identified by chance (P <
0.001 by Fisher’s exact test, observed vs. expected). For
endogenous DUX4-FL expression, the observers classified
20 of the 32 (62%) DUX4-FL-positive nuclei as obviously
different, five as maybe different (16%), and seven (22%) as
normal (P < 0.001 by Fisher’s exact test, observed vs.
expected). In contrast, only 25 of the 1010 (2%) DUX4-
FL-negative nuclei were classified as obviously different
E. SC35:   Normal 
Endogenous 
    DUX4-FL                SC35               Merge+Nuclei 
      *                         *                          * 






















Fig. 7 SC35 speckles were disrupted in many nuclei by expression of DUX4-FL from its endogenous promoter. a–d” Endogenous expression of
DUX4-FL (green) in FSHD myotubes caused SC35 speckles (red) to show an altered morphology. Arrows indicate nuclei that expressed DUX4-FL,
and asterisks indicate nearby nuclei that were DUX4-FL-negative. In panel d, the dotted line indicates where empty space was cropped from the
image so that two nearby neighboring nuclei could be juxtaposed for presentation. The most common changes to SC35 speckles in the DUX4-
FL-positive nuclei were the appearance of larger aggregates and/or more intense staining. Less common changes included loss of most speckles
(e.g., rightmost nucleus in row a) and disorganized speckles (e.g., row b). SC35 speckles were disrupted in both nuclei with punctate DUX4-FL
staining (rows a, c) and in nuclei with uniform DUX4-FL staining (row b). In nuclei with punctate DUX4-FL (rows a and c), there was little or no
overlap between DUX4-FL and SC35 staining. Some nuclei also showed little effect of DUX4-FL (e.g., leftmost nucleus in row a). e Quantitation of
SC35 speckle morphology. As described in the text, a blind test was used to classify speckle patterns into three groups: (i) similar to the majority
of controls (normal, light gray bars), (ii) maybe different from controls (medium gray bars), or (iii) obviously different from controls (dark gray bars).
Nuclei that expressed either endogenous or exogenous DUX4-FL had much higher frequencies of obviously different SC35 speckle patterns,
compared to nuclei in healthy control cultures or to nuclei that expressed exogenous DUX4-S or PITX1. Bar in a = 20 μm
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and only 43 (4%) were classified as maybe different. These
results, which are presented as a graph in Fig. 7e, implied
that the SC35 speckles in DUX4-FL-expressing cells were
sufficiently different from those in DUX4-FL-negative
cells to be accurately identified in a majority (~60–80%) of
the cases.
As further controls, we used a blind assay to examine
SC35 speckles in nuclei that expressed either DUX4-S or
PITX1 from a BacMam vector. DUX4-S was chosen
because it is a non-cytotoxic protein with the same
DNA-binding domain as DUX4-FL. PITX1 was chosen
because it is a homeodomain-containing transcription
factor that has been proposed to be regulated by DUX4-
FL and to perhaps play a role in FSHD pathology [27],
though this possibility is contested [28]. Observers clas-
sified nuclei as having obviously different SC35 staining
in 11 out of 50 (22%) DUX4-S-expressing nuclei and 1
out of 16 (6%) PITX1-expressing nuclei (Fig. 7e). Thus,
most nuclei that expressed exogenous DUX4-S or PITX1
had SC35 speckles of normal morphology and number
(Fig. 6d, e). However, DUX4-S expression did appear to
affect SC35 speckles in a subset of nuclei, though the
effect of DUX4-S was less pronounced than that of
DUX4-FL. Exogenous expression of PITX1 appeared to
have no effect on SC35 speckles.
DUX4-FL-induced co-aggregation of FUS with TDP-43
Our previous study [18] showed that DUX4-FL expression
induces nuclear aggregates of TDP-43. Because TDP-43 is
found in co-aggregates with FUS in ALS [17], we sought
to determine if FUS was also affected by DUX4-FL expres-
sion. We found that FUS nuclear aggregates were induced
by expression of DUX4-FL, either exogenously from a
BacMam vector (Fig. 8) or from its endogenous promoter
(Fig. 9), and that FUS co-aggregated with TDP-43.
When DUX4-FL was exogenously expressed in healthy
control cultures, ~40–50% of myotube nuclei showed an
altered pattern of FUS immunostaining. The altered FUS
staining in DUX4-FL-positive nuclei was characterized
either by the presence of puncta or by a nearly complete
loss of FUS staining (Fig. 8a–d) which contrasted with
the uniform stain in DUX4-negative nuclei (Fig. 8f–i). In
one experiment, for example, we examined 130 DUX4-
FL-positive nuclei and found 40 (31%) with punctate
nuclear staining (Fig. 8a–c); 14 (11%) with little or no
FUS staining (Fig. 8d); and 76 (58%) with nearly uniform
FUS staining (Fig. 8e). Punctate FUS staining was seen
in some nuclei with uniform DUX4-FL staining (Fig. 8c);
in those nuclei with a punctate pattern of DUX4-FL, the
FUS and DUX4-FL signals showed little or no overlap
(Fig. 8a, b). In contrast, FUS puncta overlapped almost
completely with TDP-43 puncta in DUX4-FL-expressing
nuclei (Fig. 9), suggesting that TDP-43 and FUS formed
co-aggregates.
The frequency of FUS puncta or decreased FUS signal
intensity was significantly higher in DUX4-FL-positive
than DUX4-FL-negative nuclei. In myoblasts and myo-
tubes of healthy controls, FUS immunostaining was
usually excluded from nucleoli but was otherwise uni-
formly distributed throughout the nucleus (Fig. 8f–i). In
one survey of 560 DUX4-FL-negative myotube nuclei in
healthy control cultures, for example, we found only 17
nuclei (3%) with puncta and 5 nuclei (1%) with little or
no staining, a result that was significantly different from
that noted above for nuclei that expressed exogenous
DUX4-FL (P < 0.001, chi-square). Myoblasts and myo-
tubes in MDC1A and LGMD2D cultures showed FUS
staining patterns that were similar to those of healthy
controls; and, in FSHD cultures, the large majority of
myotube nuclei that did not immunostain for DUX4-FL
also had the same pattern of FUS staining as healthy
controls (not shown).
Aggregation of FUS was also induced in nuclei that
expressed DUX4-FL from its endogenous promoter
(Fig. 10). We found punctate staining for FUS both in
nuclei where the staining for endogenous DUX4-FL was
punctate (Fig. 10a, b) and in nuclei where DUX4-FL
staining was more uniform (Fig. 10c). In those nuclei
with punctate staining for endogenous DUX4-FL, there
was little or no overlap between the FUS and DUX4-FL
puncta (Fig. 10a, b). As for exogenous DUX4-FL, about
half of the nuclei that expressed endogenous DUX4-FL
continued to show a nearly uniform pattern of FUS nu-
clear staining (Fig. 10d, e). In those rare FSHD myotube
nuclei that expressed endogenous DUX4-FL, a blind
assay showed that the percentage of nuclei with punctate
or low staining for FUS was significantly increased
compared to the DUX4-FL-negative nuclei in the same
culture (Fig. 9f ).
Discussion
In this study, we found that three different nuclear bod-
ies—nucleoli, PML bodies, and SC35 speckles—undergo
reorganization between the myoblast and myotube
stages of human myogenesis in vitro. In each case, the
number of bodies was decreased in myotube nuclei
compared to myoblast nuclei. In addition, nucleoli and
SC35 speckles were generally larger in myotubes than
myoblasts. Reorganization of these nuclear bodies during
normal development is consistent with a role for these
structures in regulation of the gene expression changes
that take place during myotube formation. In addition,
we found that expression of DUX4-FL in human myo-
genic cells, either from its endogenous promoter or
exogenously, disrupted the structure of a small fraction
of PML bodies and a majority of SC35 speckles. DUX4-
FL expression also induced FUS to co-aggregate with
TDP-43 in a substantial fraction of nuclei. Because
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aberrant DUX4-FL expression, particularly in skeletal
muscle, appears to be causative in FSHD, our results
suggest that DUX4-FL-induced disruption of nuclear
bodies and nuclear aggregation of FUS with TDP-43
may contribute to FSHD pathogenesis.
Our results showing nucleolar reorganization in hu-
man myogenesis are consistent with previous studies of
non-human systems. For example, we found that the
average number of nucleoli in human myogenic cells
was ~4.7 in myoblasts and ~1.9 in myotubes, and a pre-
vious study of the mouse C2C12 cell line found nearly
the same average number of nucleoli at ~5.3 in myoblasts
and ~1.7 in myotubes [15]. Also, as in the human myo-
tubes, the nucleoli in C2C12 myotubes were found to be
larger than those in myoblasts [15]. In addition, rat soleus
myofibers had an average of 1.6–1.7 nucleoli [29] and
chicken myotubes in culture had an average of 1.2–1.9
nucleoli/myonucleus, with the lower number at longer
durations of culture [30]. We additionally found that
nucleolar reorganization during myogenesis was not af-
fected in MDC1A, LGMD2D, or FSHD patient cells or by
DUX4-FL expression. The number and size of nucleoli are
Exogenous        Endogenous 



























F. FUS         G. FUS         H. FUS         I. FUS 
Fig. 8 Exogenous DUX4-FL expression induced abnormalities in FUS expression. At 24 h after addition of BacMam vector, healthy control myotubes
were examined for expression of exogenous DUX4-FL (red) and FUS (green). a–c” About 40–50% of the DUX4-FL-positive myotube nuclei showed
punctate immunostaining for FUS (panels a–c). In addition, DUX4-FL itself showed punctate staining in some nuclei and merged images indicated that
FUS and DUX4-FL puncta were not usually co-localized. d–d” About 10% of the DUX4-FL-positive myotube nuclei showed little or no staining for FUS
(panel d). e–e” The remaining approximately half of the DUX4-FL-positive myotube nuclei showed a more uniform distribution of FUS staining in the
nucleus (though excluded from nucleoli), even when DUX4-FL staining was itself punctate. f–i For comparison, myotube nuclei that did
not express DUX4-FL typically showed the more uniform pattern of FUS staining (green) without large puncta, which was similar to the
nucleus in panel e. Bar in a = 10 μm for a–e” and 8 μm for f–i
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thought to be related to cell size, stage of cell cycle, and
biosynthetic requirements [31–33], but it remains to be
determined whether these factors contribute to changes in
nucleolar number and size during myogenesis.
As with nucleoli, we found that there were fewer PML
bodies in myotube nuclei (usually 4–8) compared to
myoblast nuclei (usually 15–20), and this reorganization
was similar in MDC1A and LGMD2D cells, as well as in
DUX4-negative FSHD myotubes. Unlike nucleoli, there
was no average change in PML body size or morphology
between myoblasts and myotubes. The PML protein and
PML bodies have been shown to function in a number
of processes relevant to myogenesis. For example,
though skeletal muscle development is not markedly
affected in Pml−/− mice, expression of muscle metabolic
genes is altered, as is the regulation of cell growth and
the retinoic acid pathway [34, 35]. It may be of particular
relevance that PML is a regulator of p53-mediated cell
death [36]. We show here that, in a small subset of myo-
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F. 2
Fig. 10 Induction of nuclear aggregates of FUS by endogenous expression of DUX4-FL in FSHD myotubes. a–e” Nuclei were double stained for
endogenous DUX4-FL (red, top row) and endogenous FUS (green, lower row) in FSHD myotubes. The five nuclei illustrate a range of staining patterns
ranging from mostly large, though non-overlapping, puncta for both proteins (e.g., a, b) to more uniform staining or very small puncta (e.g., d, e). f
Quantitation of blind assays in which observers classified FUS staining patterns in DUX4-negative and DUX4-positive myotube nuclei as (i) mostly
uniform (as illustrated in Fig. 7e–i), (ii) consisting largely of punctate staining (e.g., as in a, b of this figure), or (iii) showing a low intensity signal
or no signal (e.g., as in Fig. 9d). Expression of DUX4-FL was associated with a significantly increased percentage of nuclei in which FUS showed a
punctate staining indicative of aggregation or a loss of signal intensity. Bar in a = 10 μm
A. TDP-43 B. TDP-43 
Fig. 9 Exogenous DUX4-FL expression induced nuclear co-aggregates
of FUS and TDP-43. a-a” Double immunostaining of TDP-43 (red) and
FUS (green) in myotubes which also expressed exogenous DUX4-FL
showed that TDP-43 and FUS staining were almost completely
co-localized. b–b” In rare myotube nuclei, some TDP-43 puncta
(red arrows) and FUS puncta (green arrows) did not co-localize
with the other protein, even though most of the FUS and
TDP-43 in the same nucleus were co-localized. Bar in a = 10 μm
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DUX4-FL so that PML body structure was disrupted;
and others have shown that DUX4-FL induces cell death
through a p53-dependent pathway [37, 38]. Furthermore,
DUX4-FL-mediated cell death is prevented by treatment
of cells with arsenic trioxide, a drug that inhibits p53-
mediated cell death by inhibiting the assembly of PML
bodies [39].
Though the number of SC35 speckles decreased in
myotube compared to myoblast nuclei, the ~20–25%
reduction in speckle number was of smaller magnitude
than the ~60–70% reductions in nucleoli and PML bod-
ies. A figure in a previous study showed a similar change
of SC35 speckles in mouse C2C12 myoblasts vs. myo-
tubes, but the difference was not quantified or commen-
ted on [40]. The effect of DUX4-FL expression on SC35
speckles was much more extensive than the minor effect
on PML bodies, as a majority of DUX4-FL-expressing
nuclei showed altered SC35 staining. In nuclei with a
punctate pattern of DUX4-FL staining, there was little
or no overlap of SC35 and DUX4-FL, suggesting that
these proteins did not co-aggregate.
SC35 (also known as SRSF2) is a member of the serine/
arginine-rich (SR) family of pre-mRNA splicing factors.
During the redistribution of gene loci that occurs within
myotube nuclei upon differentiation [41, 42], muscle-
specific genes become juxtaposed to the periphery of
SC35 domains [16]. This juxtaposition suggests that SC35
may play a role in the alternative splicing switching that
occur during myogenesis, as shown for beta-tropomyosin
[43]. Splicing patterns are also markedly altered by DUX4-
FL expression [39, 44]. Ventricle-specific knockout of
SC35 in developing mouse cardiomyocytes leads to hyper-
trophy and impaired excitation-contraction coupling [45],
though SC35 knockout in adult cardiomyocytes unexpect-
edly had no effect [46]. The role of SC35 in skeletal
muscle has not been tested, though, in proliferating
embryonic fibroblasts, SC35 knockout increased genomic
instability and p53 activation [46]. Thus, it is possible that
the DUX4-FL-induced alterations in SC35 speckles could
have functional consequences in one or more of several
possible pathways relevant to FSHD pathology, including
p53-mediated cell death and disruption of alternative
splicing patterns.
In addition to the DUX4-FL-induced changes in SC35
speckles, we found that DUX4-FL expression led to the
formation of FUS aggregates in nuclei. In our previous
study, we found that DUX4-FL induced similar nuclear
aggregates of TDP-43 [18]. Here, we showed that the
FUS and TDP-43 nuclear aggregates had almost com-
pletely overlapping staining patterns indicating likely co-
aggregation as often seen in ALS tissue [47, 48]. DUX4-
FL, in contrast, does not appear to co-aggregate with
FUS (this work) or with TDP-43 [18]. FUS, like TDP-43,
can bind to thousands of RNAs, as well as to single- and
double-stranded DNAs; FUS regulates multiple stages of
gene expression including transcription and splicing.
The extent to which aggregation of FUS and TDP-43
leads to gain or loss of function of either protein [48–51]
and contributes to DUX4-FL-induced pathology remains to
be determined. One approach would be to compare tran-
scriptomes and splicing patterns in DUX4-FL-expressing
myogenic cells with those in FUS and TDP-43 overexpres-
sion and knockdown cells. In our studies, we found that
both exogenous and endogenous DUX4-FL induced only
nuclear aggregates of the endogenously expressed FUS pro-
tein. We did not see the cytoplasmic FUS aggregates found
in ALS. It will be informative to identify any additional pro-
teins that may co-aggregate with FUS and TDP-43 in
muscle nuclei [52, 53] and to determine if the FUS and
TDP-43 in DUX4-FL-induced nuclear aggregates are post-
translationally modified [54, 55]. Because endogenous
DUX4-FL expression does not activate caspase-3 to a level
detectable by immunofluorescence under our culture con-
ditions [15], it appears that the nuclear aggregation of FUS
did not require cell death activation or caspase-3-mediated
cleavage of TDP-43 itself [56].
Our study adds new details to our understanding of
nuclear reorganization during normal myogenesis and to
the potentially pathological effects of aberrant DUX4-FL
expression in FSHD. Nonetheless, our study has several
limitations and many questions remain open. For ex-
ample, it will be important to examine developing and
regenerating muscles to determine if reorganization of
nucleoli, PML bodies, and SC35 speckles occurs in vivo.
Though we did not have access to appropriate human
biopsies (e.g., embryonic or regenerating muscles) for
such a study, several published studies have noted that
the nuclei in embryonic and mature myofibers, including
in humans, tend to have only one or two large nucleoli
[57–60], which is consistent with our results in vitro.
For example, Fig. 1 in Webb [57] shows a longitudinal
section of human muscle at 12 weeks in utero in which
myotube nuclei consistently show one or two nucleoli.
Unfortunately, the myoblasts in that figure were over-
stained, so nucleoli are not discernible; we have not
found other published images that show nucleoli in pro-
liferating myoblasts in vivo at high resolution or with
appropriate stains. We have also not found published
images of PML bodies or SC35 speckles in skeletal
muscles in vivo. Thus, in vivo analyses of nuclear bodies
in skeletal muscle development and disease remain for
further work.
It should also be informative to examine additional
nuclear bodies, e.g., SMN gems, coilin bodies, to deter-
mine if these bodies also reorganize during myogenesis.
Experiments in which the size or numbers of nuclear
bodies are altered, perhaps by regulating expression of the
component AluRNAs [61] or proteins, could illuminate
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the functional consequences of the size and number
changes. In addition, it will be informative to examine
FSHD muscle biopsies for signs of PML body and SC35
speckle dysfunction or co-aggregation of FUS with TDP-
43. If such signs of pathology are found, it would then be
necessary to determine if the changes correspond to sites
of concurrent DUX4-FL expression or are more wide-
spread. To develop therapies for FSHD, several groups
have developed a number of techniques to inhibit the
function or expression of DUX4-FL [37, 62, 63]. Inhibition
of DUX4-FL function or expression, if successful in
patients, might also be expected to normalize structures
of PML bodies and SC35 speckle structures and to
prevent nuclear co-aggregation of FUS and TDP-43.
Conclusions
Nucleoli, PML bodies, and SC35 speckles reorganize
during human myotube formation in vitro. These nu-
clear body reorganizations are likely needed to carry out
the distinct gene transcription and splicing patterns that
are induced upon myotube formation. DUX4-FL-
induced disruption of some PML bodies and most SC35
speckles, along with co-aggregation of TDP-43 and FUS,
could contribute to pathogenesis in FSHD, perhaps by
locally interfering with genetic and epigenetic regulation
of gene expression in the small subset of nuclei that
express high levels of DUX4-FL at any one time.
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